EuroPCR 2022 | 1 Year Outcomes of Tricuspid Valve Repair with Cardioband: Feasibility Study

Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing annulus diameter to facilitate better valve coaptation. 

A multicenter single arm study was conducted aiming at assessing the effectiveness and safety of the Cardioband safety system in the treatment of functional tricuspid failure

37 patients with tricuspid failure were included, at least moderate, symptomatic despite optimal medical treatment, with appropriate anatomy for the procedure. 

Primary end point was absence of adverse events associated to the procedure at 30 days, followed up for one year.  

Read also: EuroPCR 2022 | The IMPROVED-CTO Trial.

Patients were mean age 78±7.5, 76% were women, all of them presented severe tricuspid failure (60% torrential) and 73% pulmonary hypertension. 

When looking at major cardiovascular events, there was 8% cardiovascular mortality (unrelated to the procedure) mainly high rate of severe bleeding, both at 30 days (21%) and one year (35%), and 10% of rehospitalization for cardiac failure. 

The technique was shown effective, with 21% tricuspid annulus diameter reduction, which meant 73% reduction in tricuspid failure moderate to severe. Functional class was also improved (dyspnea in functional class CF I or II in 92% of patients).

Conclusions

Tricuspid repair with Cardioband showed high survival rate with low number of hospitalizations for cardiac failure. At one-year followup, there was significant tricuspid failure reduction and improved quality of life compared to baseline values. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented by Late-breaking clinical trial en EuroPCR 2022 por Dr William Gray.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....